Clinical Trials

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Location:

Scottsdale and Phoenix,  AZ

Trial status:

Open for Enrollment

Why is this study being done?

Study Classification: Pharmacokinetics/ Pharmacodynamics

Who is eligible to participate?

Inclusion Criteria:

- Chronic Hepatitis C, Genotype 1

- HCV RNA >100,000 IU/mL at screening;

- Seronegative for Human immunodeficiency virus (HIV) and Hepatitis B surface antigen (HBsAg);

- Liver biopsy within prior 2 years; subjects with compensated cirrhosis can enroll and will be capped at approximately 10%

Exclusion Criteria:

- Any evidence of liver disease other than HCV;

- Co-infection with HIV;

- Diagnosed or suspected hepatocellular carcinoma;

- Medical history or laboratory value abnormalities that would prohibit the use of Pegylated Interferon Alpha-2a or Ribavirin

Last updated: 03/28/2013

NCT ID: NCT01309932